semaglutide and macular degeneration Linked to Age-Related Risk GLP-1 Drugs Linked to Higher

Strengths Acts via multiple pathways (GLP-1, AMPK, microbiome) Has existing human data showing reductions in fasting glucose, HbA1c, lipids Support receptor expression and islet health Limitations Low absorption and bioavailability Gastrointestinal discomfort is common (diarrhea, cramping)

The emergence of biosimilars and cost-effective manufacturing methods may reduce financial obstacles, but need regulatory frameworks that promote competitive markets while upholding quality standards

However, to avoid possible adverse effects, it is recommended to start at 0.25 mg, which should be gradually increased over a period of 16 weeks

Cilio, M